Please try another search
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
Name | Age | Since | Title |
---|---|---|---|
Sudhir Agrawal | 69 | - | Member of Scientific Advisory Board |
Robert H.I. Andtbacka | - | - | Member of Scientific Advisory Board |
James Patrick Allison | - | 2019 | Member of Scientific Advisory Board |
Aurelien Marabelle | - | - | Member of Scientific Advisory Board |
Kjetil Hestdal | 63 | 2021 | Non-Executive Independent Director |
Jayson M. Rieger | 47 | 2021 | Non-Executive Independent Director |
Brynjar Kristian Forbergskog | 65 | 2021 | Non-Executive Independent Director |
Sandra Demaria | - | - | Member of Scientific Advisory Board |
Marie Ann Roskrow | - | 2023 | Chairperson |
Padmanee Sharma | - | 2019 | Member of Scientific Advisory Board |
Evelina Vagesjo | - | 2021 | Non-Executive Independent Director |
Marie-Louise Helena Fjallskog | 60 | 2021 | Interim CMO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review